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Abstract—The production of reactive oxygen species (ROS) within endothelial cells may have several effects, including
alterations in the activity of paracrine factors, gene expression, apoptosis, and cellular injury. Recent studies indicate that
a phagocyte-type NAD(P)H oxidase is a major source of endothelial ROS. In contrast to the high-output phagocytic
oxidase, the endothelial enzyme has much lower biochemical activity and a different substrate specificity
(NADH.NADPH). In the present study, we (1) cloned and characterized the cDNA and predicted amino acid structures
of the 2 major subunits of rat coronary microvascular endothelial cell NAD(P)H oxidase, gp91-phox and p22-phox;
(2) undertook a detailed comparison with phagocytic NADPH oxidase sequences; and (3) studied the subcellular
location of these subunits in endothelial cells. Although these studies revealed an overall high degree of homology
(.90%) between the endothelial and phagocytic oxidase subunits, the endothelial gp91-phox sequence has potentially
important differences in a putative NADPH-binding domain and in putative glycosylation sites. In addition, the
subcellular location of the endothelial gp91-phox and p22-phox subunits is significantly different from that reported for
the neutrophil oxidase, in that they are predominantly intracellular and collocated in the vicinity of the endoplasmic
reticulum. This first detailed characterization of gp91-phox and p22-phox structure and location in endothelial cells
provides new data that may account, in part, for the differences in function between the phagocytic and endothelial
NAD(P)H oxidases. (Arterioscler Thromb Vasc Biol. 2000;20:1903-1911.)
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The endothelium has a vital role in the physiologicalregulation of vascular and cardiac muscle function.
Endothelial “activation” and dysfunction are key early events
in the development of atherosclerosis and other cardiovascu-
lar disorders.1,2 It has been shown that reactive oxygen
species (ROS) generated within endothelial cells or produced
extracellularly may be involved in several aspects of these
processes. Low-level ROS production can modulate the
activity of several intracellular signaling pathways, affect the
release/activity of paracrine factors, and alter gene expres-
sion.1,3–8 Endothelial ROS may also promote apoptosis and
cellular injury, eg, during ischemia/reperfusion.9 The identi-
fication and characterization of sources of ROS within
endothelial cells are therefore of interest.
Potential sources of ROS in endothelial cells include
xanthine oxidase, nitric oxide synthases, NAD(P)H-
dependent electron transport chains, NAD(P)H-dependent
oxidoreductases, cyclooxygenase, lipoxygenase, and auto-
oxidation of tissue metabolites.1 Wolin and colleagues
(Mohazzab et al10) have shown that at a biochemical level, a
microsomal NADH oxidoreductase is a major source of ROS
in coronary endothelial cells. Recent reports suggest that at a
molecular level, this enzyme may be analogous to the
neutrophil NADPH oxidase complex.11,12 Several compo-
nents similar or identical to those of the neutrophil NADPH
oxidase complex have been detected in endothelial cells by
reverse transcription–polymerase chain reaction (RT-PCR)
and/or immunolabeling.11,12 Indirect evidence for the pres-
ence of a functional phagocyte-type NADPH oxidase in
endothelial cells also derives from studies with putative
pharmacological inhibitors of the enzyme, although these
inhibitors are not fully specific.10,12,13
The neutrophil NADPH oxidase plays a vital role in
nonspecific host defense against pathogens by generating
large (millimolar) quantities of superoxide during the so-
called respiratory burst.14 It comprises a membrane-
associated, low-potential cytochrome (cytochrome b558) and 4
or more cytosolic subunits (p47-phox, p67-phox, p40-phox,
p21rac1, and Rap1A).14–16 Cytochrome b558 is considered to
be the most important component of the complex with respect
to both enzymatic stability and activity, ie, the reduction of
molecular O2 to superoxide. Enzyme activation involves
translocation of the cytosolic components to the membrane
and association with the cytochrome. Cytochrome b558 is a
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heterodimer comprising an a-subunit (p22-phox [for phago-
cyte oxidase]) and a heavily glycosylated b-subunit (gp91-
phox), with apparent molecular weights on SDS gels of ’22
and 65 to 91 kDa, respectively. In resting neutrophils, the
NADPH oxidase is dormant but can be rapidly activated by
various receptor-dependent and -independent stimuli.
The biochemical activity of the endothelial enzyme differs
substantially from that of the phagocyte NADPH oxidase.10,12
First, the endothelial oxidase is continuously active at a low
level even in nonstimulated cells. Second, it never generates
a level of ROS comparable to the high burst activity of the
phagocytic enzyme. Third, it appears to utilize both NADH
and NADPH as substrates, but with NADH driving signifi-
cantly more superoxide production than NADPH [hence the
term NAD(P)H oxidase or NADH/NADPH oxidase],
whereas the phagocytic oxidase preferentially utilizes
NADPH. The endothelial oxidase is thus likely to subserve
different functions compared with the phagocyte oxidase. The
reasons for these differences are not known, mainly because
of the very limited characterization of the endothelial en-
zyme. In vascular smooth muscle (VSM) cells, it has been
shown recently that an NAD(P)H oxidase with similar bio-
chemical properties to those of the endothelial enzyme is
present and may be involved in the pathophysiology of
hypertension and atherosclerosis.17–20 One reason postulated
for the different activity of the VSM enzyme compared with
the phagocyte oxidase is that the gp91-phox subunit of
cytochrome b558 appears to be absent and has been suggested
to be expressed as a distinct isoform.19 Indeed, a novel protein
termed Mox1 (for mitogenic oxidase) with ’56% homology
to gp91-phox was recently reported to be expressed in VSM
cells, where it is thought to be an integral component of the
NAD(P)H oxidase.21 However, in endothelial cells, both
p22-phox and gp91-phox mRNA and protein were found to
be expressed,12 although a detailed analysis of these subunits
has not been reported.
The aims of the present study were therefore to (1) clone
and sequence the cDNAs for p22-phox and gp91-phox in rat
coronary microvascular endothelial cells (CMECs), (2) un-
dertake comparison analyses of deduced amino acid se-
quences between the endothelial cytochrome b558 subunits
(present study) and published phagocytic sequences, and
(3) study the intracellular location of these 2 subunits in
endothelial cells.
Methods
CMEC Culture
CMECs were isolated from 12-week-old male Wistar rat hearts by
retrograde collagenase digestion and differential centrifugation, ac-
cording to the method of Piper et al,22 as described previously.12 In
brief, hearts were initially perfused with the following solution
(in mmol/L): NaCl 118, KCl 4.7, NaH2PO4 1.2, MgSO4 1.2, NaHCO3
25, and glucose 11, pH 7.4, at 37°C (gassed with 95% O2/5% CO2;
buffer 1). Epicardial mesothelial cells were devitalized with 70%
(vol/vol) ethanol. Buffer 1 with added CaCl2 (0.25 mmol/L) and
collagenase (0.04%, Sigma type II) was recirculated for 30 minutes.
Ventricles, excluding visible large vessels, were chopped into 15 mL
of recirculating solution containing BSA (200 mg, Sigma fraction V)
and triturated for 10 minutes at 37°C. After filtration and centrifu-
gation (150g, 3 minutes) to remove myocytes, the supernatant was
incubated for 15 minutes at 37°C with added BSA (100 mg), trypsin
(0.01%), and CaCl2 (50 mmol/L). The CMEC pellet was obtained by
centrifugation (1000g, 10 minutes), washed, and resuspended in 40
mL of prewarmed medium 199 (Gibco) with added 10% newborn
calf serum, 10% fetal calf serum, benzylpenicillin (250 U/mL),
streptomycin (250 mg/mL), amphotericin B (12.5 mg/mL), and
gentamicin (50 mg/mL). Cell suspensions were plated in 75-cm2
culture flasks and incubated at 37°C. Unattached cells and debris
were washed off after 1 hour. Cultured cells formed confluent
monolayers within 5 to 7 days. Cells were trypsinized and subcul-
tured to confluence in fresh flasks. Cultured CMECs were charac-
terized by their typical “cobblestone” morphology, uptake of fluo-
rescently labeled acetylated LDL by .99% of cells, and the rapid
formation of capillary-like tubes on the basement membrane prepa-
ration Matrigel.12
Reverse Transcription–Polymerase Chain Reaction
Total cellular RNA was isolated by the phenol-chloroform–guani-
dinium isothiocyanate method.23 First-strand cDNA synthesis was
performed by using 10 mg of total RNA with 500 ng of random
hexamers (Promega), 10 mmol/L of each dNTP (Boehringer),
10 mmol/L Tris-HCl (pH 8.4), 50 mmol/L KCl, 2.5 mmol/L MgCl2
and 33 U of the RNase inhibitor RNasin (Promega). Reaction
mixtures were preincubated at 70°C for 3 minutes, followed by
cooling on ice for 2 minutes, before addition of 200 U of Moloney
murine leukemia virus reverse transcriptase (Gibco-BRL). RT was
performed at 42°C for 90 minutes. PCR primers for initial amplifi-
cation of p22-phox were based on the published rat aortic VSM
sequence: sense, 59-GACGCTTCACGCAGTGGTACT-39; anti-
sense, 59-CACGACCTCATCTGTCACTGG-39 (GenBank accession
No. U18729).24 Initial primers for amplification of gp91-phox were
based on the published porcine phagocyte cDNA sequence (Gen-
Bank accession No. UO2476),25 and additional primers were then
designed on the basis of partial sequence data. The primers used
were as follows: sense, 59-GTCGTCATCACGCTGTGT-39, 59-
GCCTGTGGCTGTGATAAGCAG-39, 59-GTGGTCATTACCAAGG-
TGGTC-39, and 59-ATGGTGGCGTGGATGATTGC-39 (forward
primers 1 to 4, respectively); antisense, 59-CTTTTGCAGGCCTGT-
GA-39, 59-GAACATGGGACCCACGATCCA-39, 59-GAAAATG-
TATTGTCCCACCTC-39, and 59-TTAGAAGTTTTCCTTATTG-
AA-39 (reverse primers 1 to 4, respectively). PCR was carried out in
a total volume of 100 mL containing 2 mL of RT reaction, 48 ng each
of sense and antisense primers, 200 mmol dNTPs, 1.5 mmol/L Mg21,
and 2.5 U Taq polymerase (Promega). The conditions were 25 to 35
cycles of denaturation at 94°C (1 minute), annealing at 65°C (1
minute), and extension at 72°C (2 minutes), followed by a 10-minute
extension reaction at 72°C. For sequence determinations, PCR was
carried out by using the Advantage KlenTaq polymerase mix
(ClonTech), which includes KlenTaq-1 DNA polymerase (a 59-exo-
minus, N-terminal deletion of Taq DNA polymerase), a second DNA
polymerase to provide 39359 proofreading activity, and TaqStart
antibody to provide the automatic “hotstart” PCR.26 At least 3
independent reactions were performed for each length of sequence.
5*-Rapid Amplification of cDNA Ends
These were performed by using the marathon RACE (rapid ampli-
fication of cDNA ends) cDNA amplification kit (ClonTech)
according to the manufacturer’s instructions. For amplification of
59-untranslated regions (UTRs) of p22-phox and gp91-phox,
59-AGTACCACTGCGTGAAGCGTC-39 and 59-GGCTTTGAA-
CAGTCCCTCTGTCCAGTC-39 gene-specific reverse primers
were used, respectively. These primers were designed to have
melting temperatures of at least 65°C. PolyA1 RNA was used in
first-strand cDNA synthesis, with a modified lock-docking oligo(dT)
primer that contained 2 degenerate nucleotide positions at the 39 end.
RT conditions were as described above. Second-strand cDNA was
synthesized by using a cocktail of Escherichia coli DNA polymerase
I, E coli DNA ligase, and RNase H enzymes, which degraded the
RNA before synthesis of the second-strand cDNA. Double-stranded
cDNA was blunted by T4 DNA polymerase treatment before
overnight ligation (16°C) of the marathon cDNA adapter, which was
partially double-stranded and phosphorylated at the 59 end to
facilitate blunt-end ligation of the double-stranded cDNA by T4
DNA ligase (see the ClonTech manual for further details). After
inactivation of ligase (70°C, 5 minutes), the adapter-ligated, double-
stranded cDNA was diluted in Tricine-EDTA buffer before touch-
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down PCR.27 The conditions of touchdown PCR were as follows:
94°C for 1 minute; 5 cycles of 94°C for 30 seconds, 72°C for 4
minutes; 5 cycles of 94°C for 30 seconds, 70°C for 4 minutes; and
finally 20 to 25 cycles of 94°C for 20 seconds, 68°C for 4 minutes.
3*-Rapid Amplification of cDNA Ends
To generate 39-UTRs of p22-phox and gp91-phox, thermal RACE
(single-sided or anchored PCR)28 was carried out with 2 gene-
specific forward primers for both p22-phox (No. 1, 59-GACGCTT-
CACGCAGTGGTTACT-39; No. 2, 59-GCAGTGGACTCCCATTG
AGCC-39) and gp91-phox (No. 1, 59-GTGGTCATTACC-
AAGGTGGTC-39; No. 2, 59-GCCTGTGGCTGTGATAAGCAG-
39). First-strand cDNA synthesis was performed with a “hybrid”
primer (QT), consisting of oligo(dT) (17 residues) linked to a unique
18-base oligonucleotide (“adapter”) primer Qo, which in turn was
linked to the second 18-base adapter primer Q1. RT was performed
under the conditions described previously. First-round PCR was
performed by using the adapter primer Qo, which binds to each
cDNA at its 39 end, and the gene-specific primers (No. 1) at
moderately low annealing temperatures (54°C to 60°C). In the
second-round PCR, diluted first-round PCR products were amplified
with adapter primer Q1 and gene-specific primers No. 2 under more
stringent conditions (annealing temperatures varied between 62°C
and 67°C) to minimize generation of spurious PCR products. The
sequences of the hybrid (QT) and adapter (Qo and Q1) primers were
as follows: QT, 59-CCAGTGAGCAGAGTGACGAGGACTCGA-
GCTCAAGCTTTTTTTTTTTTTTTT-39; Qo, 59-CCAGTGAGCA-
GAGTGACG-39; and Q1, 59-GAGGACTC GAGCTCAAGC-39.
Sequencing Reactions
Purified PCR products were cloned into the PCR 2.1 TA cloning
vector (Invitrogen) and transformed into E coli INVaF’-competent
cells. Selected colonies were mini-prepped by alkaline lysis, and the
DNA samples were sequenced on an automated ABI Prism 377 DNA
sequencer (Perkin Elmer). Sequencing reactions were performed at
least 3 times for each independent insert. Sequence comparisons
were made with the Match-Box web server 1.2 database available on
the Internet.29
Western Blotting
Cultured CMECs were washed twice in ice-cold PBS before lysis in
1 mL of boiling lysis solution containing 1% SDS and 10 mmol/L
Tris (pH 7.4). Protein concentrations were quantified by a micro–
bicinchoninic acid assay kit (Pierce). Equal amounts of protein (100
mg for p22-phox and 200 mg for gp91-phox) were run on 8% to 10%
SDS polyacrylamide gels and electroblotted onto nitrocellulose
membranes. Equal rates of transfer were confirmed by reversible
staining with Ponceau S (Sigma). Membranes were incubated over-
night at 4°C with primary antibodies, and peroxidase-conjugated
secondary antibodies were used. The various anti–cytochrome b558
antibodies used were all originally raised against human neutrophil
NADPH oxidase. Monoclonal antibodies against p22-phox (449) and
gp91-phox protein (48) were provided by Dr A. Verhoeven (Am-
sterdam, Holland).30 An anti–p22-phox rabbit polyclonal antibody
(antibody a) was provided by Dr F. Wientjes (University College
London, UK).31 and an anti–gp91-phox rabbit polyclonal (KQS) was
provided by Dr M. Quinn (Montana State University, Montana,
USA).32
Confocal Immunofluorescence Microscopy
CMECs grown on coverslips were permeabilized and fixed with
methanol ( 220°C for 5 minutes).33 Coverslips were washed and
incubated with 20% fetal calf serum in PBS (pH 7.4) before
incubation with different primary antibodies in PBS with 0.1% BSA
and 0.01% NaN3. Bodipy (4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene) fluorescein thapsigargin (Molecular Probes), which binds
to the endoplasmic reticulum Ca21-ATPase, was used as a fluores-
cent marker for the endoplasmic reticulum and was used instead of
the primary antibody at a concentration of 5 mmol/L (in 0.1% BSA
in PBS, pH 7.4, at 37°C for 1 hour). These slides were washed and
incubated with 0.1% BSA in PBS instead of the secondary antibody;
in all other respects, these slides were subjected to the same protocol
as those prepared for immunocytochemistry. For rabbit polyclonal
antibodies, anti-rabbit cy3 (Amersham) was used as the secondary
antibody. For mouse monoclonal antibodies, anti-mouse cy3 (Am-
ersham) was used for single-antibody slides, and anti-mouse–FITC
(Sigma) was used on dual-labeled slides. Rabbit IgG (1 mg/mL) was
used instead of the primary antibody for negative controls. Two
slides were prepared for each primary antibody (or combination) on
each of the 3 batches of CMECs isolated, making a total of 6 slides
examined for each. Confocal microscopy was performed with a
Leica TCS4D microscope equipped with an argon/krypton laser.33
The excitation wavelength was 568 nm for the cy3 conjugate and 488
nm for the FITC conjugate and bodipy FL thapsigargin. There was
no overlap in fluorescence emission between these probes; ie,
excitation at 568 nm elicited no significant FITC fluorescence in
samples that were single-labeled with an FITC-conjugated antibody.
For x-y sections of field size 100 mm2 (single-labeling studies), the
3100 objective was used, and for 200 mm2 (double-labeling stud-
ies), the 340 objective. With a pinhole setting of 60 mm, this gave
a depths of focus of ’0.5 and 1 mm for the 3100 and 340
objectives, respectively.
Results
Characterization of p22-phox cDNA in Rat
Cultured CMECs
With the use of primers based on the previously published rat
aortic VSM p22-phox cDNA sequence,24 PCR resulted in
485-bp (expected size) products from each of several CMEC
cDNA samples. A PCR product of identical size was ampli-
fied from the human monocyte–like macrophage cell line
U937, which expresses cytochrome b558 components at high
levels.34 Negative controls performed without RT did not
yield any PCR products, indicating an absence of genomic
DNA contamination (data not shown). The rest of the
p22-phox cDNA, including 59- and 39-UTRs, was amplified
by RACE reactions. Cloning and sequencing revealed a
695-bp cDNA for rat CMEC p22-phox, containing an open
reading frame of 579 bp and encoding 192 amino acid
residues (Figure 1), with a predicted molecular weight of just
under 21 kDa. A comparison of the deduced amino acid
sequence of rat CMEC p22-phox with the previously pub-
lished rat VSM sequence24 and with several neutrophil
p22-phox sequences35–38 revealed a high degree of homology:
100% with the rat VSM, 87% with the human and porcine
neutrophil, and 85% with the murine neutrophil sequence
(Figure 2). Northern blot analysis of rat CMECs with the
sequenced and cloned PCR product as a probe yielded a
single band of molecular size 0.8 kb (data not shown), in
Figure 1. cDNA sequence and deduced amino acid sequence
for rat endothelial cell p22-phox.
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agreement with the size of p22-phox mRNA in neutrophils of
several species.35–38
Characterization of gp91-phox cDNA in Rat
Cultured CMECs
Initial PCR with primers based on the previously published
porcine macrophage gp91-phox sequence25 resulted in a
987-bp expected-size PCR product from each of several rat
CMEC cDNA samples. U937 cell cDNA was used as a
positive control, and samples without RT were used as
negative controls to exclude genomic cDNA contamination
(not shown). The rest of the CMEC gp91-phox cDNA was
obtained by further PCR and RACE reactions. Cloning and
sequencing of the rat CMEC gp91-phox cDNA revealed an
open reading frame of 1713 bp encoding a primary translation
product of 570 amino acid residues (Figure 3), with a
predicted molecular weight of 65 349 Da and a calculated
isoelectric point of 8.90. Figure 4 shows the comparative
deduced amino acid alignment between rat CMEC gp91-phox
and published bovine,38 human,39 porcine,25 and murine40
neutrophil gp91-phox cDNA sequences, starting from the first
potential initiation codon found in the sequences. There was
substantial homology between the rat CMEC sequence and
the neutrophil gp91-phox sequences (.90% at the amino acid
level) but also a number of potentially significant differences
(see Discussion).
The relative abundance of gp91-phox mRNA in CMECs
appeared to be significantly less than that of p22-phox,
because 35 cycles of amplification compared with 25 to 28
cycles for the p22-phox transcript were required. In keeping
with this, gp91-phox mRNA could not be detected by
Northern blotting (data not shown).
Expression and Subcellular Location of p22-phox
and gp91-phox Proteins
The expression of p22-phox protein was confirmed by West-
ern blotting with either a monoclonal or a polyclonal anti-
neutrophil p22-phox antibody (449 and a, respectively), each
directed against different epitopes of the protein.30,31 Both
antibodies detected an ’22- to 23-kDa band in CMECs as
well as in U937 cells (Figure 5). We have previously reported
the expression of gp91-phox protein in rat CMECs in Western
blots with the use of a monoclonal anti-neutrophil gp91-phox
antibody (48).12 A polyclonal anti-neutrophil gp91-phox an-
tibody (KQS) directed against a different epitope of the
protein32 also detected an ’91-kDa band in CMECs (Figure
5C). In addition, a band at ’60 to 65 kDa was also detected,
which may represent deglycosylated protein.41 In human
neutrophil membrane, the KQS antibody reacted with a broad
smear from ’55 to 100 kDa, as described previously.14,32
This smearing pattern is thought to be due to variable
glycosylation of gp91-phox. Of note, we did not detect a
similar smearing pattern with CMEC protein with either of
the anti–gp91-phox antibodies used.
The subcellular location of p22-phox and gp91-phox in rat
CMECs was addressed by confocal immunofluorescence
microscopy, using the same antibodies as reported above for
Figure 2. Comparison of predicted rat
CMEC p22-phox peptide sequence with
published rat VSM cell and various
phagocyte p22-phox sequences. Aster-
isk denotes a conserved histidine resi-
due thought to be involved in heme
binding. The proline-rich region num-
bered 1 is thought to be involved in
binding p47-phox. Bold letters indicate
positions where the amino acid residue
in 1 sequence is different from all other
sequences.
Figure 3. cDNA and deduced amino acid sequence for rat en-
dothelial cell gp91-phox.
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Western blotting. Figure 6A shows x-y confocal sections of
CMECs labeled with either of the 2 anti–p22-phox antibodies
(a and 449, respectively) or with either of the 2 anti–gp91-
phox antibodies (KQS and 48, respectively). A consistent
pattern of labeling was seen with each of the 4 antibodies: a
predominantly perinuclear distribution but also a more dif-
fuse reticular staining extending toward the cell membrane.
This panel of images also shows the background controls
with rabbit nonspecific IgG instead of the primary antibody.
Figure 6B shows x-y confocal sections of CMECs dual-
labeled with an anti–p22-phox and an anti–gp91-phox anti-
body in different combinations (1 monoclonal and 1 poly-
clonal). These sections demonstrated colocalization of gp91-
phox and p22-phox subunits (a148 and KQS1449,
respectively). The images were entirely consistent with those
of each antibody used alone (see Figure 6A). As a marker of
the plasma membrane, antibody to the G-protein b-subunit
(Santa Cruz) was used, and it showed a typical sarcolemma-
restricted distribution and a characteristic sharp outline of
these cells (Figure 6B, bottom right). The labeling pattern
observed for the 2 NADPH oxidase subunits was found to be
very similar to that obtained with bodipy FL thapsigargin,
which binds to the endoplasmic reticulum Ca21-ATPase
(Figure 6B, bottom left).
Discussion
The phagocyte NADPH oxidase is a well-characterized
superoxide-generating complex that is vital for microbicidal
activity.14–16 Molecular defects in oxidase components result
in chronic granulomatous disease, which is characterized by
impaired or absent NADPH oxidase activity and a propensity
to recurrent, life-threatening infections.14 Recently, compo-
nents of phagocyte-type NADH/NADPH oxidases have been
found in several nonphagocytic cell types, including fibro-
blasts,42,43 VSM cells,19,24 coronary endothelial cells,11,12
renal mesangial cells,44 chemoreceptor cells,45 microglia,46
and bone osteoclasts.47 In these nonphagocytic cells, it is
notable that ROS production is generally of relatively low
magnitude and slow kinetics compared with the burstlike
millimolar production of the activated neutrophil NADPH
oxidase. Potential explanations for this difference could
include the possibility that oxidase subunit structures (partic-
Figure 4. Comparison of predicted rat CMEC
gp91-phox peptide sequence with published
phagocyte gp91-phox sequences of 4 different spe-
cies. Asterisks denote conserved histidine residues
considered to be involved in heme binding and
coordination. Regions A and B are putative flavin-
binding domains, whereas regions C through F are
putative NADPH-binding domains. Region G
denotes the flavin shield. Underlined motifs N-X-
(S/T) marked with the symbol Ù are potential glyco-
sylation sites. Bold letters indicate positions where
the amino acid residue in 1 sequence is different
from all other sequences.
Figure 5. Western blots showing expression of p22-phox and
gp91-phox protein. A, Detection of p22-phox with monoclonal
antibody in U937 cells (lane 1), rat CMECs (lane 2), and rat VSM
cells (lane 3). B, Detection of p22-phox with polyclonal
a-antibody in U937 cells (lane 1) and rat CMECs (lane 2). C,
Detection of gp91-phox with polyclonal KQS antibody in human
neutrophil membrane (lane 1) and in rat CMECs (lane 2).
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ularly that of gp91-phox) and/or subunit expression level,
stoichiometry, and location are different among the enzymes.
Indeed, in VSM, a protein with ’56% homology to gp91-
phox, termed Mox1, appears to substitute for gp91-phox in
the NAD(P)H oxidase.21
gp91-phox in Rat CMECs
A detailed comparison between the deduced amino acid
sequence of rat gp91-phox (present study) and published
phagocyte gp91-phox sequences from several species (pig,25
mouse,40 human,39 and cow38) indicates a high (.90%)
overall degree of homology (Figure 4). For example, only 35
of 570 amino acids are different between the predicted rat
CMEC sequence and the porcine macrophage gp91-phox
sequence, which was used as the initial template for PCR
amplification. Furthermore, at many of these residues, there is
similarity to the phagocytic sequences of other species.
Significant information is available as to the putative
functional and structural domains of phagocyte gp91-phox,
much of it deriving from studies of patients with chronic
granulomatous disease.14–16 The histidine residues (at 101,
115, 209, and 222) located in putative transmembrane regions
and potentially involved in heme binding and coordination
are fully conserved among all sequences. His 115 has been
suggested to be important for the H1 channel function of
gp91-phox.48 His 338, which is also conserved in the endo-
thelial sequence, is suggested to be a critical residue for FAD
incorporation and thus, enzyme activity.49 The 2 potential
flavin-binding domains (A and B in Figure 4) are both fully
conserved. The gp91-phox molecule has 4 putative NADPH-
binding domains (labeled C through F in Figure 4), based on
homology to ferrodoxin NADP1 reductase and other related
flavoproteins.14,15 Although domains D through F are fully
conserved, a striking difference occurs at residue 416 in
domain C in the rat CMEC sequence, where serine is
substituted for the phenylalanine present in all of the phago-
cyte sequences. Interestingly, a missense mutation resulting
in substitution of histidine for proline has been reported at
Figure 6. Subcellular localization of p22-phox and gp91-phox in rat CMECs by confocal immunofluorescence microscopy. A, Top pan-
els show labeling with either a polyclonal or a monoclonal anti–p22-phox antibody (a and 449, respectively). Middle panels show label-
ing with either a polyclonal or a monoclonal anti–gp91-phox antibody (KQS and 48, respectively). Bottom panels are negative controls
with nonspecific IgG. All scale bars are 10 mm. The depth of focus for this panel of pictures was 0.5 mm. B, Top panels show dual
labeling with a polyclonal anti–p22-phox antibody and a monoclonal anti–gp91-phox antibody (a and 48, respectively). Middle panels
show dual labeling with a monoclonal anti–p22-phox antibody and a polyclonal anti–gp91-phox antibody (449 and KQS, respectively).
Bottom left panel shows labeling with a fluorescent endoplasmic reticulum marker, bodipy FL thapsigargin. Bottom right panel shows
plasma membrane labeling with an anti–Gb-protein antibody. All scale bars are 10 mm. The depth of focus for this panel of pictures
was 1.0 mm.
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residue 415 in chronic granulomatous disease patients, which
results in decreased binding of NADPH to the oxidase and
significantly reduced neutrophil O22 production.50 The non-
conservative substitution at residue 416 in the rat CMEC
sequence could therefore also be potentially functionally
important, with respect to both enzyme activity and substrate
specificity. Another notable difference between the rat
CMEC sequence and the phagocyte sequences is in potential
glycosylation sites, which are encoded by the consensus motif
N-X-(S/T), where X is any residue. The deduced rat CMEC
sequence contains 3 potential glycosylation sites, namely
residues 40 to 42, 97 to 99, and 430 to 432 (Figure 4). In
contrast, the murine phagocyte sequence contains 4 potential
glycosylation sites, and the human and bovine contain 5 each.
(The porcine phagocyte sequence shown in Figure 4 has 4
potential glycosylation sites, but this sequence is considered
to be incomplete.) For human neutrophil gp91-phox, it was
suggested that the actual targets for glycosylation are residues
132 to 134, 149 to 151, and 240 to 242.41 None of these 3
regions are consensus glycosylation motifs in the rat CMEC
sequence. This difference could account for the finding that
rat CMEC gp91-phox migrates as discrete, ’91- and ’60- to
65-kDa bands, whereas the phagocytic proteins generally
migrate as a broad smear from ’55 to 100 kDa. Because
glycosylation may influence protein assembly, subcellular
location, intracellular transport, and stability,51 this difference
may also account for the intracellular location of rat CMEC
gp91-phox in the vicinity of the endoplasmic reticulum
(Figures 6A and 6B). The putative p47-phox–binding do-
mains of gp91-phox (residues 87 to 94, 451 to 458, 494 to
498, and 559 to 565) are all conserved in the rat CMEC
sequence. It remains feasible that differences in regions of the
protein to which no functional activities have been so far
assigned might be important.
p22-phox in Rat CMECs
The coding region and 39-UTR of the rat CMEC p22-phox
cDNA sequence determined in the present study show 100%
homology to the previously published rat VSM sequence.24
Comparison of the rat CMEC p22-phox predicted amino acid
sequence with those of published neutrophil sequences from
several species (pig,37 mouse,36 human,35 and cow38) reveals
considerable (.90%) homology (Figure 2). It is notable that
the histidine residue (His 94) suggested to be a potential
heme-binding site is conserved in all sequences. Proline-rich
SH3-binding regions in the carboxy terminus of p22-phox (in
particular, residues 151 to 160), which are suggested to be
involved in binding SH3 domains in p47-phox, are also highly
conserved in all sequences. None of the differences between
the rat CMEC/VSM p22-phox sequence and published neu-
trophil sequences suggests a significant difference between
the proteins.
Protein Expression and Subcellular Location of
p22-phox and gp91-phox
The expression of the 2 cytochrome b558 subunits at the
protein level was also confirmed in CMECs. In the case of
gp91-phox, the pattern of labeling on Western blots was
different from the neutrophil pattern, as discussed above.
With respect to subcellular location, a consistent labeling
pattern was obtained with all of the anti–gp91-phox and
p22-phox antibodies used in CMECs. Notably, the majority
of labeling was clearly intracellular and appeared to be in the
vicinity of the endoplasmic reticulum, as judged by the
similar staining pattern observed with an endoplasmic retic-
ulum marker. The validity of this result was reinforced by the
fact that dual labeling, either with 2 anti–gp91-phox or 2
anti–p22-phox antibodies, or with a combination of 1 each,
always resulted in colocalization. In neutrophils, previous
studies with electron microscopy and immunogold labeling
demonstrated that cytochrome b558 is localized mainly in
granulocytes, which may fuse with the plasma membrane
when neutrophils are activated.52 A similar study with anti–
gp91-phox antibody to label “unroofed” neutrophils, with the
cytoplasmic face of the plasma membrane exposed, showed
NAD(P)H oxidase subunits to be clustered in microdomains
of the plasma membrane.31 Our results suggest that in
CMECs the location of NAD(P)H complex is significantly
different, with most of the enzyme being clearly located
intracellularly. Given the high overall homology in structure
and putative transmembrane domains between the endothelial
gp91-phox sequence and published phagocyte sequences, it
seems likely that the cytochrome b558 subunits in endothelial
cells are bound to intracellular membranes. However, the
resolution of fluorescent confocal microscopy used in the
present study is insufficient to establish whether the
NAD(P)H oxidase subunits are indeed attached to the endo-
plasmic reticulum or possibly, in granules associated with it.
Confirmation of the precise intracellular location would
probably require electron microscopy and immunogold label-
ing studies.
Conclusions
An analysis of cDNA and predicted amino acid sequences of
the 2 major components of NAD(P)H oxidase, p22-phox and
gp91-phox, and their subcellular location in rat CMECs has
been undertaken in the present study. Determination of the
full rat CMEC gp91-phox cDNA sequence represents the first
analysis of a gp91-phox sequence in a nonphagocytic cell
type. The results indicate a number of structural differences
(notably in putative NADPH binding and in glycosylation
sites) that could contribute to the low but sustained biochem-
ical activity of the endothelial oxidase. In addition, the
subcellular location of the endothelial oxidase differs from
that reported for the neutrophil enzyme, perhaps reflecting a
different function. However, it remains feasible that factors
such as the availability of heme and other cofactors,53 a low
expression level of other subunits,54 or a defective activation
process55 could also contribute to the biochemical differences
between the endothelial and phagocyte enzymes. Determina-
tion of the cDNA structure of the a- and b-subunits of
endothelial NAD(P)H oxidase paves the way for further
investigation of structure-function relations of this complex
enzyme system.
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